Alcon to acquire LENSAR for $430m.

Alcon, a pharmaceutical and medical device company, agreed to acquire LENSAR, a medical technology company focused on advanced laser solutions for the treatment of cataracts, for $430m. “We are excited for the opportunity to bring LENSAR’s unique next-generation technologies and intellectual property into our innovative, market-leading equipment portfolio. By leveraging our global footprint, we have the opportunity to deliver the benefits of advanced femtosecond laser technology to many more surgeons around the world and continue to improve efficiency in cataract surgery,” David Endicott, Alcon CEO.